Section Arrow
AVTE.NASDAQ
- Aerovate Therapeutics
Quotes are at least 15-min delayed:2024/05/16 17:55 EDT
Last
 21.91
+0.9 (+4.28%)
Day High 
22.48 
Prev. Close
21.01 
1-M High
25.58 
Volume 
252.07K 
Bid
21.91
Ask
25.27
Day Low
20.8187 
Open
21.23 
1-M Low
18.37 
Market Cap 
603.77M 
Currency USD 
P/E -- 
%Yield
10-SMA 20.4 
20-SMA 20.95 
50-SMA 24.19 
52-W High 32.415 
52-W Low 9.41 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.87/-1.90
Enterprise Value
604.03M
Balance Sheet
Book Value Per Share
3.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1001+0.0224+28.83%-- 
DNAGinkgo Bioworks Holdings0.839-0.0001-0.01%-- 
NBYNovaBay Pharmaceuticals0.12+0.0155+14.83%-- 
JAGXJaguar Health0.2867+0.0316+12.39%-- 
NVAXNovavax14.4+1.5+11.63%-- 
Quotes are at least 15-min delayed:2024/05/16 17:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powderinhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.